3 Poster Session 3

Late-occurring and long-circulating metabolites of GABAA receptor modulator AZD7325 involving metabolic cyclization and aromatization: relevance to MIST analysis and application for patient compliance
Chungang (Chuck) Gu, AstraZeneca; Markus Artelsmair, AstraZeneca; Charles S Elmore, AstraZeneca; Patty Davis, AstraZeneca; James E Hall, AstraZeneca; Richard J Lewis, AstraZeneca; Bruce Dembofsky, AstraZeneca; Greg Christoph, AstraZeneca; Michael Ramaker, AstraZeneca; Mark A Smith, AstraZeneca; Marc Chapdelaine, AstraZeneca; Maria Sunzel, AstraZeneca
HUMAN BIOTRANSFORMATION PATHWAYS OF THE ORAL PROTEASOME INHIBITOR IXAZOMIB: METABOLITE PROFILING OF [14C]-IXAZOMIB IN PLASMA AND EXCRETA OF PATIENTS WITH ADVANCED SOLID TUMORS
Sandeepraj Pusalkar, Millennium Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Michaela Plesescu, Millennium Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Neeraj Gupta, Millennium Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Michael Hanley, Millennium Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Karthik Venkatakrishnan, Millennium Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Jing-Tao Wu, Millennium Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cindy Xia, Millennium Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Swapan Chowdhury, Millennium Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
PHASE 1 STUDY TO EVALUATE THE ABSORPTION, METABOLISM AND EXCRETION OF THE NAV1.7-SELECTIVE SODIUM CHANNEL BLOCKER BIIB074
Caroline Woodward, Biogen; Himanshu Naik, Biogen; Mark Versavel, Biogen; Lin Xu, Biogen; Xiaopeng Miao, Biogen; Hao Sun, Covance Inc.; Mark Gohdes, Drug Metabolism and Disposition, Covance Laboratories Inc.; Joi Dunbar, Biogen
Metabolism of GA(17:1) in rat liver microsomes, human liver microsomes, recombinant human CYPs and UGTs
Mingcheng Xu, Institue of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research; Li Li, Institue of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research; Su Zeng, Institue of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research
FRACTIONAL CONTRIBUTION OF CYP AND UGT ENZYMES TO THE DISPOSITION OF CANNABINOIDS
Gabriela Patilea-Vrana, University of Washington; Jashvant D. Unadkat, University of Washington
Structure-activity Relationship of Phenoxyaniline Congener Interactions with Cytochrome P450 2B Enzymes
Chao Chen, School of Pharmacy, University of Connecticut; Jingbao Liu, University of Connecticut; P. Ross Wilderman, University of Connecticut; James R. Halpert, University of Connecticut
A Novel Systematic Approach for Screening of Prodrugs Designed to Improve Oral Absorption
Mai Shimizu, Drug Metabolism & Pharmacokinetics Research Laboratories, Central Pharmaceutical Research Institute, JAPAN TOBACCO INC.; Toshio Taniguchi, Drug Metabolism & Pharmacokinetics Research Laboratories, Central Pharmaceutical Research Institute, JAPAN TOBACCO INC.; Yukihiro Nomura, Drug Metabolism & Pharmacokinetics Research Laboratories, Central Pharmaceutical Research Institute, JAPAN TOBACCO INC.; Motohiro Kogayu, Drug Metabolism & Pharmacokinetics Research Laboratories, Central Pharmaceutical Research Institute, JAPAN TOBACCO INC.
IN VITRO CUTANEOUS METABOLISM OF TRIOCTANOIN AND TRANSCUTANEOUS PASSAGE OF 2-ETHYLHEXANOIC ACID
Beatrice Lopez, EUROSAFE; Fabrice Guillet, EUROSAFE; Solenne Martin, EUROSAFE; Christophe Chesne, EUROSAFE; Pierre Jaques Ferret, PIERRE FABRE DERMO COSMETIQUE
An Open-label, Two-period Study Designed to Evaluate and Compare the Mass Balance Recovery and Metabolite Profile of 14C Deutetrabenazine and 14C-Tetrabenazine in Healthy Male Subjects
Margaret Bradbury, Teva Pharmaceutical Industries Ltd; David Stamler, Teva Pharmaceutical Industries Ltd; Thomas Baillie, University of Washington; Stuart Mair, Quotient Clinical; Sharan Sidhu, Quotient Clinical; Stuart G Wood, Pharmaron UK Ltd; Iain Shaw, Quotient Clinical
Human Pharmacokinetics and Mass Balance Study of Beloranib using LC-MS/MS
Philip Inskeep, Inskeep DMPK; Frank Hsieh, Nextcea; Nanjun Liu, Nextcea; Elizabeth Tengstrand, Nextcea; Elena Ryzhikova, Nextcea; James Vath, Zafgen; Jaret Malloy, Zafgen; Sandy Bertelsen-Purika, Zafgen; Michael Gartner, Celerion
PROTEIN ABUNDANCE OF PHARMACOKINETICALLY RELEVANT TRANSPORTER PROTEINS AND METABOLIZING ENZYMES ALONG THE HUMAN INTESTINE AND IN THE LIVER: A COMPARATIVE INTRA-SUBJECT STUDY
Marek Drozdzik, Pomeranian Medical University; Diana Busch, University Medicine of Greifswald; Janett Müller, University Medicine of Greifswald; Joanna Lapczuk, Pomeranian Medical University; Marek Ostrowski, Department of Experimental and Clinical Pharmacology, Pomeranian Medical University; Mateusz Kurzawski, Pomeranian Medical University; Stefan Oswald, University Medicine of Greifswald
An Analysis of the Xenobiotic Metabolism Portfolio: Highlights from the National Institute of Environmental Health Sciences Extramural Division
Danielle J Carlin, National Institute of Environmental Health Sciences; Brittany Trottier, National Institute of Environmental Health Sciences; William A Suk, National Institute of Environmental Health Sciences
Comparing Induced and Non-induced Rat Brain Microsomes from Xenotech.
Ying Liu, Biogen Idec; Jiansheng Huang, Biogen Idec; Kevin Westland, XenoTech LLC; Aaron Hilgedick, XenoTech LLC; Stephanie Helmstetter, XenoTech LLC; Mukesh Lulla, Biogen Idec; Josh Johnson, Biogen Idec; Mohammad Shadid, Biogen Idec
Using Ion Mobility LC-MS and LC-MS/MS to resolve and identify isobaric glucuronide metabolites
Jayne Kirk, Waters Corporation; Rachel Sanig, Waters Corporation; Russell Mortishire-Smith, Waters Corporation; Sherri Naughton, Waters Corporation; Yun Alelyunas, Waters Corporation; Mark Wrona, Waters Corporation
Purification of Biosynthesized Drug Metabolites by Supercritical Fluid Chromatography
Pingrong Liu, Boehringer Ingelheim; Zaid Temrikar, Boehringer Ingelheim; Heewon Lee, Boehringer Ingelheim; Amy Gao, Boehringer Ingelheim; Nina Gonnella, Boehringer Ingelheim; Dongyue Xin, Boehringer Ingelheim; Mitchell E Taub, Boehringer Ingelheim; Aaron Teitelbaum, Boehringer Ingelheim
Utility of Pooled Cryopreserved Human Enterocytes as An In Vitro Model for Assessing Intestinal Clearance and Drug-Drug Interactions
Susan Wong, Genentech Inc.; Utkarsh Doshi, In Vitro ADMET Laboratories LLC; Peter Vuong, Genentech Inc.; Ning Liu, Genentech Inc.; Suzanne Tay, Genentech Inc.; Hoa Le, Genentech Inc.; Jane Kenny, Genentech Inc.; Albert P. Li, In Vitro ADMET Laboratories LLC; Zhengyin Yan, Genentech Inc.
Evaluation of Rat Brain Subcellular Fractions for the Prediction of In vivo Drug Metabolism in Brain
Mohammad Shadid, Biogen Idec; Ying Liu, Biogen Idec; Elvana Veizaj, Biogen Idec; Jiansheng Huang, Biogen Idec; Josh Johnson, Biogen Idec; Amin Kamel, Takeda
THE BENZYLIC ALCOHOL METABOLITE OF TRIMETHOPRIM COVALENTLY BINDS TO PROTEINS IN VITRO
Jennifer L Goldman, Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Hospital; J. Steven Leeder, Children's Mercy Hospital; Leon van Haandel, Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Hospital
EVIDENCE OF CIRCULATING TRIMETHOPRIM PROTEIN ADDUCTS IN HUMAN PLASMA
Leon van Haandel, Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Hospital; Ryan Funk, University of Kansas Medical Center; J. Steven Leeder, Children's Mercy Hospital; Jennifer L Goldman, Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Hospital
Downstream metabolism of a glutathione conjugate of an arene oxide intermediate
Steve Bowlin, Takeda; Natalie Hosea, Takeda; Donavon McConn, Takeda; Amin Kamel, Takeda
EFFECT OF TWO PRETREATMENT REGIMENS OF 1-AMINOBENZOTRIAZOLE ON METABOLISM AND GASTRIC EMPTYING OF PROBE COMPOUNDS IN RAT
Vinay K Holenarsipur, Syngene International Ltd, BBRC,; Shweta Padmanabhan, Syngene International Ltd, BBRC,; Harbeer Kaur, Syngene International Ltd, BBRC,; Abhijith Rao, Syngene International Ltd, BBRC,; Yogesh Gupta, Syngene International Ltd, BBRC,; Thanga Mariappan, Syngene International Ltd, BBRC,
A comparison of adult and neonatal human hepatocytes in drug metabolizing enzyme activities
Albert P. Li, In Vitro ADMET Laboratories Inc.; David Ho, In Vitro ADMET Laboratories Inc.; Nick Ring, In Vitro ADMET Laboratories Inc.; Kirsten Amaral, In Vitro ADMET Laboratories Inc.
Identification of Human CYP Enzymes Involved in the Metabolism of 14C‑SRD005825
Gang Luo, Covance Laboratories Inc.; Devin Welty, Shire; Sara Leitz, Covance Laboratories Inc.; Jody Wanta, Drug Metabolism and Disposition, Covance Laboratories Inc.; Daniel Albaugh, Covance Laboratories Inc.; Serene Josiah, Shire; Donald McKenzie, Covance Laboratories Inc.; Zhen Lou, Shire
Metabolism of 14C-SRD005825 in Mouse, Rat, Dog, Monkey, and Human Hepatic Microsomes
Zhen Lou, Shire; Thiago Braga, Drug Metabolism and Disposition, Covance Laboratories Inc.; Devin Welty, Shire; Serene Josiah, Shire; Jody Wanta, Drug Metabolism and Disposition, Covance Laboratories Inc.; Sara Leitz, Covance Laboratories Inc.; Mark Gohdes, Drug Metabolism and Disposition, Covance Laboratories Inc.; Daniel Albaugh, Covance Laboratories Inc.; Amy Nehmer, Covance Laboratories Inc.; Donald McKenzie, Covance Laboratories Inc.; Gang Luo, Covance Laboratories Inc.
Alteration in the intrinsic clearance of CYP2B6 by NAFLD: evidence of the involvement of the metabolic syndrome in variable drug response
Enoch Cobbina, University of Rhode Island; Anitha Saravanakumar, Univeristy of Rhode Island; Fatemeh Akhlaghi, University of Rhode Island
I-screen: In vitro platform to study human gut microbiota induced drug metabolism and molecular transformations 
Steven Erpelinck, TNO; Frank H.J. Schuren, TNO; Irene H.G. Nooijen, TNO; R. Scott Obach, Pfizer Inc.; Gregory S. Walker, Pfizer Inc.; Evita van de Steeg, TNO; Wouter H. Vaes, TNO
Metabolic Profiles of Benzydamine in Humanized-liver Mice
Makiko Shimizu, Showa Pharmaceutical Univ; Hiroshi Suemizu, Central Institute for Experimental Animals; Hiroshi Yamazaki, Showa Pharmaceutical Univ
CHARACTERIZATION OF XATHINE OXIDASE ACTIVITY IN CYTOSOL OF PRE-CLINICAL SPECIES AND ALLOPURINOL FREE HUMAN CYTOSOL TO BETTER ELUCIDATE METABOLIC CLEARANCE PATHWAYS
Timothy J. Strelevitz, Pfizer Global R & D; Richard P. Schneider, Pfizer Worldwide Research and Development; Christine C. Orozco, Pfizer Inc.; Matthew Cerney, Pfizer Inc.
Aldehyde Oxidase Dependent Metabolite Profiling Methodologies in Early Drug Discovery Projects
Lloyd M King, UCB Biopharma; Jehan Claessens, UCB Biopharma; Christelle Derwa, UCB Biopharma; Liz Jones, UCB Biopharma; Anne Foley, UCB Biopharma; Emre M Isin, UCB Biopharma; Nenad Manevski, UCB Biopharma; Harold Mackenzie, UCB Biopharma
Stereoselective Metabolism of Pyrido[3,2-d]pyrimidine-containing Compounds by Aldehyde Oxidase
Xiaowei He, Eisai Inc.; Y. Amy Siu, Eisai Inc.; W. David Hong, University of Liverpool; Farid Benayoud, Eisai Inc.; W. George Lai, Eisai Inc.
POSTNATAL EXPRESSION AND TISSUE DISTRIBUTION OF FLAVIN-CONTAINING MONOOXYGENASE 3 (FMO3)
Zhen Xu, University of Rhode Island; Bingfang Yan, University of Rhode Island
Dissecting CYP3A interactome to understand the causes of CYP3A variability
Danxin Wang, The Ohio State University; Rong Lu, The Ohio State University; Grzegorza Rempala, The Ohio State University; Wolfgang Sadee, The Ohio State University
Enantiomer-Specific Warfarin Metabolism Characterized by Pharmocogenomic Profiling and Chiral LCMS
Cheryl Bartleson, Worldwide Clinical Trials; Eduardo Lopez, Worldwide Clinical Trials; Steve Unger, Worldwide Clinical Trials; Karin M Keller, Worldwide Clinical Trials
CLINICAL GENOTYPING ASSAY FOR PERSONALIZED DOSING OF DICHLOROACETATE
Peter W. Stacpoole, University of Florida; Richard Wagner, Medosome Biotec LLC; Taimour Langaee, University of Florida; Lloyd Horne, University of Florida; Petr Starostik, University of Florida; Lee Ann Lawson, University of Florida
Improved progression-free survival in metastatic colorectal cancer patients carriers of the HNF1A coding variant p.I27L treated with irinotecan
Adrien Labriet, Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University; Elena Demattia, Clinical and Experimental Pharmacology, “Centro di Riferimento Oncologico”- National Cancer Institute; Erika Cecchin, Clinical and Experimental Pharmacology, “Centro di Riferimento Oncologico”- National Cancer Institute; Éric Lévesque, CHU de Québec Research Center and Faculty of Medicine, Laval University; Derek Jonker, Division of Medical Oncology, Department of Medicine, Ottawa Hospital, University of Ottawa; Félix Couture, CHU de Québec Research Center and Faculty of Medicine, Laval University; Angela Buonadonna, Medical Oncology Unit, “Centro di Riferimento Oncologico”- National Cancer Institute; Mario D’Andrea, Medical Oncology Unit, “San Filippo Neri Hospital”; Lyne Villeneuve, Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and Faculty of Pharmacy, Laval University; Giuseppe Toffoli, Clinical and Experimental Pharmacology, “Centro di Riferimento Oncologico”- National Cancer Institute; Chantal Guillemette, Canada Research Chair in Pharmacogenomics, CHU de Québec Research Center
Pharmacogenetic analysis of OATP1B1 variants in relation to the pharmacokinetics of Grazoprevir and the efficacy of Zepatier (Elbasvir and Grazoprevir) in HCV infected subjects from previously conducted clinical studies.
Zifang Guo, Merck & Co Biostatistics and Research Decision Science, Merck Research Laboratories; Luzelena Caro, Merck & Co Quantitative Pharmacology and Pharmacometrics, Merck Research Laboratories; Michael N Robertson, Merck & Co Clinical Research, GCD, Merck Research Laboratories; Jacqueline Mccrea, Merck & Co Translational Pharmacology, Merck Research Laboratories; Patricia Hoover, Merck & Co Clinical Pharmacogenomics; Christen Wudarski, Merck & Co Clinical Pharmacogenomics; Kristina Maiuri, Merck & Co Clinical Pharmacogenomics; Ying-Hong Wang, Merck & Co Quantitative Pharmacology and Pharmacometrics, Merck Research Laboratories; Robin Mogg, Merck & Co Biostatistics and Research Decision Science, Merck Research Laboratories; Devan Mehrotra, Merck & Co Biostatistics and Research Decision Science, Merck Research Laboratories; Rebecca Blanchard, Merck & Co Clinical Pharmacogenomics; Peter M Shaw, Merck & Co Clinical Pharmacogenomics
A novel physiologically based pharmacokinetics (PBPK) approach for human PK prediction
Kei Mayumi, Research Laboratory for Development, Shionogi & Co., Ltd.; Takanobu Matsuzaki, Research Laboratory for Development, Shionogi & Co., Ltd.; Satoko Funaki, Research Laboratory for Development, Shionogi & Co., Ltd.; Shingo Sakamoto, Research Laboratory for Development, Shionogi & Co., Ltd.; Shuichi Ohnishi, Research Laboratory for Development, Shionogi & Co., Ltd.; Hiroshi Hasegawa, Research Laboratory for Development, Shionogi & Co., Ltd.
Use of Efficient Property-Dose-Response Simulations to Drive Compound Optimization
Kefeng Sun, Eli Lilly and Company; Evan Wang, Eli Lilly and Company
Kinetic estimation of 131I labeled anti-EGFR antibody for development of a radioimmunotherapeutic agent based on an organ distribution study in tumor bearing mice using 125I-cetuximab
Byoung Soo Kim, Korea Institute of Radiological and Medical Science; Jong Guk Kim, Korea Institute of Radiological and Medical Sciences; Sang June Jeon, Korea Institute of Radiological and Medical Sciences; Doo Hyun Yoon, Korea Institute of Radiological and Medical Sciences; Tae Hyun Choi, Korea Institute of Radiological and Medical Science
TRITIATED ANTISENSE OLIGONUCELOTIDES – RADIOSYNTHESIS AND PHARMACOKINETIC INVESTIGATIONS
Stephen Harris, Pharmaron UK Ltd; Kathryn Webbley, Pharmaron UK Ltd; Claire Henson, Pharmaron UK Ltd; Stephanie Geoffroy, Pharmaron UK Ltd; Stuart G Wood, Pharmaron UK Ltd; Ray Cooke, Pharmaron UK Ltd; Adrian Waring, Pharmaron UK Ltd; Jon Bloom, Pharmaron UK Ltd; Vernon Wilson, Pharmaron UK Ltd; Calvin Hawes, Pharmaron UK Ltd; Darren Price, Pharmaron UK Ltd; Jack Haffenden, Pharmaron UK Ltd
Comparative approaches between Quantitative-MSI and Quantitative-WBA: application to Chloroquine administration in a Long-Evans Male Rat model.
Guillaume Hochart, Imabiotech; Joseph Marini, Covance Laboratories Inc.; Aurore Tomezyk, Imabiotech; Phil Manteufel, Covance; Bonnie Jung, Covance Laboratories Inc; Stefan Linehan, ImaBiotech Corp; Donald McKenzie, Covance Laboratories Inc.; Jonathan Stauber, Imabiotech
ESSENTIAL OILS OF CULINARY HERBS AND SPICES MODULATE THE TRANSCRIPTIONAL ACTIVITY OF HUMAN ARYLHYDROCARBON RECEPTOR
Iveta Bartonkova, Faculty of Science, Palacky University Olomouc; Zdenek Dvorak, Faculty of Science, Palacky University in Olomouc,
P450 INDUCTION IN CRYOPRESERVED HEPATOCYTES FROM PXR AND CAR NUCLEAR RECEPTOR KNOCK-OUT RATS
Kevin P Forbes, Horizon Discovery - SAGE Labs; Kirsten Amaral, In Vitro ADMET Laboratories LLC; Albert P Li, In Vitro ADMET Laboratories Inc. (IVAL)
LXR/FXR AGONIST ALTERS TRANSPORTER EXPRESSION IN SANDWICH-CULTURED HUMAN HEPATOCYTES; PROTEOMICS-DRIVEN PBPK MODELING IMPLICATES A DRUG-DRUG INTERACTION WITH METFORMIN
Katsuaki Ito, The University of North Carolina at Chapel Hill; Kim L.R. Brouwer, The University of North Carolina at Chapel Hill
OCT2 INHIBITION USING CREATININE AS AN IN VITRO PROBE SUBSTRATE AS A PREDICTOR OF CLINICAL EFFECT
Pallabi Mitra, Boehringer Ingelheim; Lalitha Podila, Boehringer Ingelheim; Meeghan Michalewicz, Boehringer Ingelheim; Mitchell E Taub, Boehringer Ingelheim
ABUNDANCE & RELATIVE SEGMENTAL EXPRESSION OF INTESTINAL TRANSPORTERS IN CAUCASIANS: A META-ANALYSIS
Matthew D Harwood, Simcyp Ltd (a Certara company); Mian Zhang, Simcyp Ltd (a Certara company); Shriram Pathak, Simcyp Ltd (a Certara company); Iain Gardner, Simcyp Ltd (a Certara company); Sibylle Neuhoff, Simcyp Ltd (a Certara company)
AN ABSOLUTE TRANSPORTER ABUNDANCE APPROACH FOR IN VITRO-IN VIVO EXTRAPOLATION OF INTESTINAL TRANSPORTER ACTIVITY
Matthew D Harwood, Simcyp Ltd (a Certara company); David B Turner, Simcyp Ltd (a Certara company); Iain Gardner, Simcyp Ltd (a Certara company); Sibylle Neuhoff, Simcyp Ltd (a Certara company)
Influence of Human Drug Transporter Activities by Environmental Pollutants
Nie Jing, Institue of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research; Su Zeng, Institue of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research
Fampridine is a substrate and inhibitor of human OCT2, but not MATE1 and MATE2K
Christopher Rowbottom, Biogen Idec; Carri Boiselle, Biogen; Lawrence Gan, BiogenIdec; Tonika Bohnert, Biogen; Guangqing Xiao, Biogen
Progress towards the phenotyping of solute carrier transporters in human primary hepatocytes
Yi-An Bi, Pfizer Global Research & Development; Manthena Varma, Pfizer Inc.
EVALUATION OF TRANSCELLULAR TRANSPORT OF ATENOLOL IN POLARIZED MDCKII CELLS STABLY EXPRESSING HUMAN PMAT AND OCT1
Yoshihisa Mimura, Graduate School of Pharmaceutical Sciences, Nagoya City University; Tomoya Yasujima, Graduate School of Pharmaceutical Sciences, Nagoya City University; Kinya Ohta, College of Pharmacy, Kinjo Gakuin University; Katsuhisa Inoue, Tokyo University of Pharmacy and Life Sciences; Hiroaki Yuasa, Nagoya City University
EVALUATION OF DECYNIUM-22 AS A SPECIFIC INHIBITOR OF ENBT1
Risa Takenaka, Graduate School of Pharmaceutical Sciences, Nagoya City University; Yosuke Hishikawa, Graduate School of Pharmaceutical Sciences, Nagoya City University; Tomoya Yasujima, Graduate School of Pharmaceutical Sciences, Nagoya City University; Kinya Ohta, College of Pharmacy, Kinjo Gakuin University; Katsuhisa Inoue, Tokyo University of Pharmacy and Life Sciences; Hiroaki Yuasa, Nagoya City University
Novel in Vitro Method to Predict in Vivo Liver-to-Plasma Unbound Partition Coefficient
Li Di, Pfizer Inc.; Keith Riccardi, Pfizer, Inc.; Zhenhong Li, Pfizer Inc.; Jian Lin, Pfizer, Inc.; Sangwoo Ryu, Pfizer Inc.; Mark Niosi, Pfizer Inc.
CELLULAR UPTAKE TRANSPORT MECHANISMS OF DOXORUBICIN AND THEIR POTENTIAL CONTRIBUTION TO DRUG EFFICACY AND SAFETY
Markus Keiser, University Medicine of Greifswald; Marcus Otter, University Medicine of Greifswald; Susanne Csader, University Medicine of Greifswald; Sandra Bien-Moeller, University of Greifswald; Stefan Oswald, University Medicine of Greifswald
PH-DEPENDENT AFFINITY OF KETAMINE TO P-GP, OCT AND MATE TRANSPORTERS
Markus Keiser, Center of Drug Absorption and Transport (C_DAT), University Medicine of Greifswald; Mahmoud Hasan, Center of Drug Absorption and Transport (C_DAT), University Medicine of Greifswald; Stefan Oswald, Center of Drug Absorption and Transport (C_DAT), University Medicine of Greifswald
NEW INSIGHTS OF THE INTESTINAL LOCALIZATION OF THE ORGANIC ANION TRANSPORTING POLYPEPTIDE 2B1 (OATP2B1)
Markus Keiser, Center of Drug Absorption and Transport (C_DAT), University Medicine of Greifswald; Janett Müller, University Medicine of Greifswald; Charlotte Wildberg, Center of Drug Absorption and Transport (C_DAT), University Medicine of Greifswald; Lars Kaltheuner, Center of Drug Absorption and Transport (C_DAT), University Medicine of Greifswald; Lars-Ivo Partecke, Department of General Surgery, Visceral, Thoracic and Vascular Surgery, University Medicine of Greifswald; Claus-Dieter Heidecke, Department of General Surgery, Visceral, Thoracic and Vascular Surgery, University Medicine of Greifswald; Stefan Oswald, Center of Drug Absorption and Transport (C_DAT), University Medicine of Greifswald
Establishing a platform of uptake transporters in HEK-293 cells for the analysis of possible drug-drug-interactions
Jia Jia, PRIMACYT Cell Culture Technology GmbH; Anett Ullrich, PRIMACYT Cell Culture Technology GmbH; Claudia Garve, PRIMACYT Cell Culture Technology GmbH; Dieter Runge, PRIMACYT Cell Culture Technology GmbH; Markus Keiser, Center of Drug Absorption and Transport (C_DAT), University Medicine of Greifswald
Time-Dependent Inhibition of Drug Transporters
Robert Yucha, Takeda Boston; Bei-Ching Chuang, Takeda Boston; Chiharu Fukushi, Takeda Japan; Kimio Tohyama, Takeda Japan; Masanori Nakakariya, Takeda California; Nobuyuki Amano, Takeda Japan; Swapan Chowdhury, Takeda Boston; Mingxiang Liao, Takeda Boston
Human MDR1 and BCRP expressing MDCKII double knockout cells (Mdr1-/-/Bcrp-/-) towards more predictive drug transport studies.
Tseten Y Jamling, Hera BioLabs; Andrew Parkinson, XPD Consulting; Wei Zhang, Hera BioLabs
Characterization of Bile Acid Sulfate Conjugates as Substrates of Human Organic Anion-Transporting Polypeptides
Christine Orozco, Pfizer Inc.; Yi-an Bi, Pfizer Inc.; Matthew Cerney, Pfizer Inc.; Sumathy Mathialagan, Pfizer Inc.; Laurie Tylaska, Pfizer Inc.; Brian Rago, Pfizer Inc.; Anna Vildhede, Pfizer Inc.; Chester Costales, Pfizer Inc.; A. David Rodrigues, Pfizer Inc.
COMPLEX METHAMPHETAMINE INHIBITION KINETICS OF ORGANIC CATION TRANSPORTER 2 (OCT2)
David J Wagner, University of Washington; Jennifer E. Sager, University of Washington; Nina Isoherranen, University of Washington; Joanne Wang, University of Washington
Assay calibration to refine prediction of P-gp mediated DDI based on in vitro vesicular transport assay data
Zsuzsanna Nerada, SOLVO Biotechnology; Beáta Tóth, SOLVO Biotechnology; Emese Kis, SOLVO Biotechnology; Joseph K. Zolnerciks, SOLVO Biotechnology USA; Zsuzsanna Gáborik, SOLVO Biotechnology
DETERMINATION OF FRACTION OF A DRUG TRANSPORTED BY RAT OATPS THROUGH IDENTIFICATION AND USE OF SELECTIVE OATP INHIBITORS
Kazuya Ishida, University of Washington; Mohammed Ullah, F. Hoffmann-La Roche Ltd; Beáta Tóth, SOLVO Biotechnology; Viktória Juhász, SOLVO Biotechnology; Jashvant D. Unadkat, University of Washington
pH sensing mechanism of human equilibrative nucleoside transporter 3 involved in mitochondrial transport of nucleoside analog drugs 
Md Fazlur Rahman, The Ohio State University; Rajgopal Govindarajan, The Ohio State Univerity
Circadian expression of hepatic drug transporters and their role in the hepatic excretion of phenolsulfonphthalein
Ju-Hee Oh, Division of Biopharmaceutics, College of Pharmacy, Kyung Hee University; Miri Kim, Department of Life and Nanopharmaceutical Sciences, College of Pharmacy, Kyung Hee University; Joo Hyun Lee, Division of Biopharmaceutics, College of Pharmacy, Kyung Hee University; Sehyung Cho, Neurodegeneration Control Research Center & Department of Physiology, College of Medicine, Kyung Hee University; Dong-Hee Han, Neurodegeneration Control Research Center & Department of Physiology, College of Medicine, Kyung Hee University; Young-Joo Lee, Department of Life and Nanopharmaceutical Sciences, College of Pharmacy, Kyung Hee University
Evidence for the Role of OATP and PEPT1 Transporters in the Intestinal Apical Transport of Amoxicillin
Christine M. Lee, UNC Eshelman School of Pharmacy; Dhiren R. Thakker, UNC Eshelman School of Pharmacy
EXPRESSION AND TRANSCRIPTIONAL AS WELL AS EPIGENETIC REGULATION OF METABOLIZING ENZYMES AND TRANSPORTER PROTEINS IN INTESTINAL CELL LINES
Anja Fritz, University Medicine of Greifswald; Susanne Brück, University Medicine of Greifswald; Janett Müller, University Medicine of Greifswald; Stefan Oswald, University Medicine of Greifswald
Evaluation of SRD005825 as a Substrate and Inhibitor of a Panel of Human Drug Transporters
Gang Luo, Covance Laboratories Inc.; Devin Welty, Shire; Serene Josiah, Shire; Manuela Gast, Covance Laboratories Inc.; Deborah Lee, Covance Laboratories Inc.; Ryan Keehn, Covance Laboratories Inc.; Daniel Albaugh, Covance Laboratories Inc.; Donald McKenzie, Covance Laboratories Inc.; Zhen Lou, Shire
Inhibition of BSEP and MDR3 Activity by Statins in Primary Human Hepatocytes
Kan He, Biotranex; Qin Shi, Biotranex; Thomas Woolf, Biotranex; Lining Cai, Biotranex
Gestational Age-dependent Abundance of Drug Transporters and Metabolizing Enzymes in Human Placentae Quantified by LC-MS/MS Proteomics
Olena Anoshchenko, University of Washington; Bhagwat Prasad, University of Washington; Jashvant D. Unadkat, Univ of Washington
See more of: General Abstracts